New Data Support Viral Suppression as Key to Preventing HIV Transmission
May 3rd 2019Results of the recent study, published in The Lancet, support the benefits of early testing and treatment for HIV, as well as the message of Prevention Access Campaign’s U=U (undetectable equals untransmittable) initiative.
Read More
Ivosidenib as Monotherapy Granted FDA Approval for Certain Patients with IDH1 Mutant AML
May 3rd 2019The sNDA was granted Priority Review and accepted under the agency's Real-Time Oncology Review pilot program, which aims to make the review of oncology drugs more efficient by allowing the FDA access to clinical trial data before the information is formally submitted to the agency.
Read More
Ivosidenib as Monotherapy Granted FDA Approval for Certain Patients with IDH1 Mutant AML
May 3rd 2019The sNDA was granted Priority Review and accepted under the agency's Real-Time Oncology Review pilot program, which aims to make the review of oncology drugs more efficient by allowing the FDA access to clinical trial data before the information is formally submitted to the agency.
Read More
First Vaccine for Dengue Disease Prevention Receives FDA Approval
May 2nd 2019The drug application was granted the FDA’s Priority Review designation, as well as a Tropical Disease Priority Review Voucher under a program intended to encourage development of new drugs and biologics for the prevention and treatment of certain tropical diseases.
Read More
Walgreen's, UC College of Pharmacy Partner for Specialty Pharmacy Education
May 1st 2019Partnerships like the UC College of Pharmacy and Walgreens offer opportunities for experience with complex disease states, such as cancer, multiple sclerosis, HIV, and Crohn’s disease, that many students will see after they graduate.
Read More
Bipolar Disorder: Opportunity for Pharmacists to Improve Adherence and Health Outcomes
As highly accessible health care professionals, pharmacists have the opportunity to improve medication adherence and health outcomes of patients with bipolar disorder.
Read More
First Treatment for All Genotypes of Hepatitis C in Pediatric Patients Granted FDA Approval
April 30th 2019The safety and efficacy of the glecaprevir and pibrentasvir in pediatric patients was evaluated during clinical trials of 47 patients with genotype 1, 2, 3 or 4 HCV infection without cirrhosis or with mild cirrhosis.
Read More